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Summary
Idiopathic calcium oxalate (CaOx) stone-formers (ICSFs) differ from patients who make 
idiopathic calcium phosphate (CaP) stones (IPSFs). ICSFs, but not IPSFs, form their stones as 
overgrowths on interstitial apatite plaque; the amount of plaque covering papillary surface is 
positively correlated with urine calcium excretion and inversely with urine volume. The amount of 
plaque predicts the number of recurrent stones. The initial crystal overgrowth on plaque is CaP, 
although the stone is mainly composed of CaOx, meaning that lowering supersaturation (SS) for 
CaOx and CaP is important for CaOx stone prevention. IPSFs, unlike ICSFs, have apatite crystal 
deposits in inner medullary collecting ducts, which are associated with interstitial scarring. ICSFs 
and IPSFs have idiopathic hypercalciuria, which is due to decreased tubule calcium reabsorption, 
but sites of abnormal reabsorption may differ. Decreased reabsorption in proximal tubules (PTs) 
delivers more calcium to the thick ascending limb (TAL), where increased calcium reabsorption 
can load the interstitium, leading to plaque formation. The site of abnormal reabsorption in IPSFs 
may be the TAL, where an associated defect in bicarbonate reabsorption could produce the higher 
urine pH characteristic of IPSFs. Preventive treatment with fluid intake, protein and sodium 
restriction, and thiazide will be effective in ICSFs and IPSFs by decreasing urine calcium 
concentration and CaOx and CaP SS and may also decrease plaque formation by increased PT 
calcium reabsorption. Citrate may be detrimental for IPSFs if urine pH rises greatly, increasing 
CaP SS. Future trials should examine the question of appropriate treatment for IPSFs.
Introduction
The common measures of reduced diet sodium and protein, increased fluids, thiazide, 
potassium citrate, reduced diet purine, and allopurinol have until now been viewed from the 
perspective of altering urine supersaturations and inhibitors of crystallization. Here, we add 
to this familiar theme the new work concerning how stones actually form and how the 
mechanisms that drive their formation actually function. The result is a new level of 
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understanding in the use of accepted treatments that should bring to physicians and their 
patients a greater confidence and subtlety of management.
The new work has divided calcium stone-formers not only by their clinical appearances but 
also their renal pathology. We have always distinguished patients who form calcium stones 
because of systemic disease from idiopathic calcium stone-formers. However, we now know 
that idiopathic calcium stone-formers whose stones are predominantly calcium oxalate differ 
markedly from those whose stones are not. This new distinction has real clinical effects and 
calls for a new trial.
Idiopathic Calcium Oxalate Stone-Formers
Stones Grow over Deposits of Interstitial Apatite (Plaque)
In the most common kind of patient, calcium stones arise from no systemic disease but are, 
rather, “idiopathic.” Among these, most (1) form stones for which the most abundant crystal 
is calcium oxalate (CaOx). The kidneys of idiopathic CaOx stone-formers (ICSFs) are 
normal except for papillary interstitial apatite deposits (2,3) that appear as white clouds 
(Figure 1A) under the urothelium during ureteroscopy (URS) or percutaneous 
nephrolithotomy (PERC). The kidney stones grow over these deposits, often called “white 
plaque,” on the outside of the papilla (Figure 1B). No crystals are seen within the epithelial 
compartments (4). The deposits evoke no obvious inflammation, and renal papillae are 
completely normal in appearance except for plaque and overgrowing stones.
Plaque begins as collections of tiny microspherules that form in the basement membranes of 
the papillary thin limbs of the loops of Henle (Figure 1C) and spread from there into the 
interstitium and eventually beneath the urothelium and basement membranes of inner 
medullary collecting ducts (IMCDs) and terminal ducts of Bellini (BDs), where they appear 
as white plaque (Figure 1D).
In a prospective study of ICSFs, all stones visualized using PERC were classified as attached 
or not, and those attached were further classified as attached or not to plaque (5). Most 
stones were attached, and of those, all were attached to plaque or their attachment site could 
not be fully verified. Verification required that intraoperative classification during surgery 
agree with subsequent classification from intraoperative digital video recordings. Despite 
some difficulties with verification, the results were overwhelmingly in favor of the 
supposition that attachment is the rule and attachment is virtually always over plaque. In a 
follow-up study of the unattached stones, most were found to possess apatite surface foci 
that could have been an attachment to interstitial plaque (6). The main implication of this 
work is that plaque is essential to stone formation, and if so, plaque abundance and numbers 
of recurrent stones should correlate; in fact, they do, a finding that strengthens the stone-
plaque link (7).
Because CaOx stones in ICSFs grow outside of the nephron and over plaque, the main issues 
for clinicians concern reduction of overgrowth, given plaque, and prevention of plaque itself. 
Until recently, we have used our treatments exclusively for the first purpose; we now have 
reasons to consider both purposes within clinical reach.
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Formation of Plaque
Urine Risk Factors—The fraction of papillary surface covered by plaque varies with 
urine calcium (8), and it varies inversely with urine volume and pH (Figure 2). A 
multivariate score derived from all three measurements accounts for a high fraction of the 
variation in plaque abundance between ICSFs and normal controls. To clinicians, this means 
that high urine volume and control of urine calcium, both prudent means for stone reduction, 
ought to also benefit plaque formation.
Physiologic Links between Urine Findings and Plaque—How these urine factors 
affect plaque requires a deeper look into the renal physiology involved, and such a look 
increases the nuance and subtlety of clinical management. In the papillae, thin limbs are 
surrounded by three to four capillaries each (Figure 3, lower panels). The calcium 
concentration of thin limb fluid exceeds that of blood levels because of water extraction (9), 
but the epithelium possesses very low calcium permeability and does not transport calcium 
at all (10). Even so, thin limb fluid is always in contact with its epithelium, so calcium must 
move into the basement membrane at a higher concentration than blood, especially in the 
ascending portion that does not permit extensive water movement. However, the outer side 
of the basement membrane can lose calcium into the surrounding interstitium at a rate that is 
inversely related to the calcium molarity of the interstitial fluid, and that molarity will 
inevitably be dominated by the calcium concentration of the blood delivered to the 
capillaries.
That blood comes down in the descending vasa recta, which form bundles in the inner stripe 
of the outer medulla that are surrounded by a ring of thick ascending limbs (11) (Figure 3, 
upper panels). Thick ascending limbs reabsorb calcium without water mainly via a lumen 
positive transepithelial potential created by the sodium-potassium-chloride cotransporter 2 
and the renal outer medullary potassium channel. (10). Delivery of calcium without water 
must enrich the inner stripe interstitium with calcium, and this must in turn raise the calcium 
concentration of blood in the descending vasa recta. So, in all conditions, the basement 
membranes of the papillary thin limbs will be bathed on both sides by fluid with a calcium 
concentration above that of blood: lumen fluid via water extraction, interstitial fluid via vasa 
washdown.
This probably accounts for why interstitial plaque forms even in normal people and initiates 
in this particular site; however, so far we have not explained why plaque would be more 
abundant in ICSFs than in normal people because the anatomy and functions of thin limbs 
and thick ascending limbs are essentially alike.
Idiopathic Hypercalciuria—The crucial difference lies in how calcium is managed in 
ICSFs as opposed to normal people. Populations of men and women exhibit a wide range of 
urine calcium excretions from as low as <50 to as high as >500 mg daily, with mean values 
in the range of 130 to 170 mg daily for both genders (12). ICSFs appear to have been 
selected from the high tail of this distribution because their mean values are twice that of 
normal individuals. Like height, calcium excretion is seemingly genetically determined 
because high values run in families (13) and rodents can be bred for it (14). Such high urine 
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calcium excretion is not a disease, but merely the cause of high stone risk in more 
hypercalciuric people. ICSFs are said to have idiopathic hypercalciuria (IH), but a better way 
to think about the matter is that they simply are drawn from one end of the normal genetic 
endowment of humankind.
In humans and in animals, IH reflects increased tissue vitamin D activation: intestinal 
calcium absorption and bone mineral mobilization are increased, and a low-calcium diet can 
cause negative bone mineral balance (13). But of interest here is how more calcium than 
normal gets into the urine. It could be from increased blood calcium because the calcium 
from each meal is absorbed at an abnormally brisk pace; it could be from reduced tubule 
calcium reabsorption. In fact, it is the latter (15). Eating fixed and identical high-calcium and 
normal diets, ICSFs with IH reduce overall tubule reabsorption with each meal more than 
matched controls, so that at identical serum calcium levels and calcium-filtered loads they 
excrete more calcium.
This would not be sufficient to explain higher plaque in ICSFs than normal except we add 
that, using endogenous lithium clearance as a marker, the proximal tubule participates in the 
reduction of overall tubule calcium reabsorption (16), and as a consequence, delivery of 
calcium into the thin limbs is abnormally high (Figure 4). In this figure each point represents 
15 clearance periods in ICSFs (black circles) or controls (gray circles) taken throughout a 
three-meal day in the general clinical research center. Compared with controls, ICSFs 
deliver far more calcium distally, and urine calcium excretion parallels distal delivery 
reasonably well.
The thin limbs do not reabsorb calcium appreciably, so increased distal delivery means 
increased calcium enters the thick ascending limbs where it is reabsorbed via mainly 
electrogenic forces. This means that more delivery will generally result in correspondingly 
more reabsorption, without water, into the interstitium of the outer stripe of the inner 
medulla. In turn, descending vasa recta will be more preloaded with calcium, and the 
capillaries of the papillum will enrich the interstitium with calcium to a greater degree, 
thereby fostering crystal nucleation in thin limb basement membranes. In the broadest sense, 
one would expect plaque abundance to parallel urine calcium excretion, which it does. Of 
course, interstitial calcium concentrations must be measured in human tissues if this 
hypothesis is to be properly tested; such measurements can be made, and we hope that 
investigators take on this specific test as a research aim. Failure to find increased interstitial 
calcium would defeat our hypothesis.
Effects of Urine Volume on Plaque—This model also predicts that plaque abundance 
will be generally inverse to urine volume. Vasopressin, a major agonist of medullary thick 
ascending limb transport, acting via the V2 receptor, is highest when urine volume is low, 
and the converse. Moreover, medullary washout from high urine flows will tend to reduce 
the concentrations of all papillary interstitial solutes, including calcium.
Limitations of This Model—We present this work as in progress and of value because it 
leads to further tests. For example, lithium clearance is not a direct measurement of proximal 
tubule reabsorption and may be subject to errors. Other tests (e.g., increase of urine calcium 
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after blockade of the thick ascending limb by furosemide) would be valuable confirmation 
(17), as would, perhaps, studies of free water clearances. Likewise, Figure 4 makes it clear 
that not all of our ICSFs display the same degree of proximal tubule alteration, but we 
cannot presently correlate proximal reabsorption with plaque abundance measurements. This 
latter comparison would be a critical test of the hypotheses we propose and can be 
performed in human subjects.
Clinical Measures That May Reduce Plaque Formation
Because plaque cannot be quantified in patients except during surgery, randomized 
controlled trials (RCTs) for plaque prevention are not as yet practical, but from what we 
have already presented clinicians can derive some reasonably sound directions that have no 
risk and high potential benefit.
Reduced diet sodium and protein, long mentioned for moderation of hypercalciuria (18), 
may increase proximal tubule reabsorption. The first acts via reduction of extracellular fluid 
volume. The second reduces endogenous acid production from oxidation of sulfur on 
methionine and cystine; acid loads reduce proximal reabsorption (19). Thiazide-type 
diuretics are a mainstay in stone prevention (20) because they lower urine calcium excretion. 
In rodents, and presumably humans as well, they increase proximal reabsorption by reducing 
extracellular fluid volume (21). High water intake, an obvious stone prevention supported by 
RCTs (22), will reduce vasopressin, and therefore medullary thick ascending limb 
reabsorption (23), and foster medullary solute washout. One might consider once-a-night 
nocturia for patients whose stones recur despite all other measures because urine volume is 
lowest and vasopressin is presumably highest overnight.
After only one stone, we advise only modest treatment efforts (24), but one might consider 
that plaque needs to form before ICSFs can make stones and that stone recurrence tends to 
parallel plaque abundance (7). Given this point, high fluids and reduced diet protein and 
sodium would be reasonable as soon as possible in the natural history of stone disease, 
meaning with the first stone.
Even at the first stone, and often during the course of the disease, surgeons will have access 
to at least a coarse-grained visual assessment of plaque abundance via URS or PERC. We 
see every advantage in asking surgeons to share their best impression with us. Given a lot of 
plaque, stone prevention efforts may best be pushed as far as possible and patients made 
aware of a higher underlying risk of recurrence. This latter may increase their desire to 
maintain prevention treatments, especially those pertaining to diet and fluid intake.
How Stones Grow on Plaque
At the attachment site of a 1-mm CaOx stone (Figure 5) the urothelium over a plaque 
deposit was disrupted, and the plaque surface was exposed to urine (25). The exposed 
surface was sealed by an inner boundary of organic material of urine origin, containing 
Tamm–Horsfall protein and osteopontin as well as other molecules. Apatite crystals 
nucleated in the layer, were covered by more organic matrix, new nucleation occurred, and 
ultimately alternating crystal and organic layers formed a laminated ribbon. The ribbon 
terminated when crystallization spread out into the urinary space forming the stone base. In 
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this transmission electron micrograph, plaque is at the lower left, white arrowheads show the 
inner boundary layer, and crystals are shown at the stone base by an asterisk and double 
arrows. The inset shows the details of the ribbon and its crystals at higher magnification.
The crucial steps in the process, in addition to formation of plaque itself, are disruption of 
the urothelium, about which we know nothing at the present time, and the initial apatite 
nucleation, which drives the formation of the new stone. This nucleation depends entirely 
upon urine calcium phosphate (CaP) supersaturation (SS), meaning that even in CaOx stone-
formers, CaP SS is a critical clinical variable to control as best one can.
In ICSFs, CaP SS far exceeds normal (Figure 6, lower right panel), to an even greater extent 
than for CaOx SS (Figure 6, upper right panel). Normal people do not, on average, achieve 
CaP SS values >1, meaning that the initial apatite nucleation might be rare indeed, whereas 
values in ICSFs are >1 virtually all of the time (26). The highest values of CaP SS are late 
afternoon and overnight for ICSFs, when the SS of normal people declines modestly. The 
high CaP SS is driven by high urine calcium molarity (Figure 6, upper left panel), itself 
arising from IH without any corresponding increase of urine volume (Figure 6, lower middle 
panel). Differences in urine pH are minimal between ICSFs and normal individuals (Figure 
6, lower left panel).
One must think it odd that urine volume is not higher in ICSFs than normal people given that 
the apical collecting duct calcium receptor (CaSR) should sense the rising calcium molarity 
and reduce water reabsorption; however, the facts are simply that this does not occur. For 
example, overnight, calcium molarity among ICSFs reaches near 6 mM whereas normal is 2 
mM, but urine volumes are identical. The CaSR is probably protective, but only at higher 
levels of urine calcium excretion. The human CaSR studied in vitro is half stimulated at 
calcium ion molarities of 6 at the pH and ionic strength of urine, but in human urine a total 
calcium molarity of 6 means only approximately 3 mM calcium ion. The remaining urine 
calcium is bound in complexes that help create SS, such as with phosphate and oxalate. So 
the lack of effect in our patients is not actually divergent from what one might expect.
Clinical Measures That May Reduce Stone Overgrowth on Plaque
Reduction of CaP SS may be as important as reduction of CaOx SS even in ICSFs. High 
urine volume should help, as might all measures to reduce urine calcium, including reduced 
diet sodium and protein and thiazide. Overnight is so remarkably a time of high CaP SS, 1× 
nocturia could be important in refractory patients. In other words, means of treatment are the 
same as for plaque.
However, potassium citrate is complex, if of probable value. Alkalis reduce urine calcium 
excretion and increase proximal tubule reabsorption via reduced diet net acid load (27), and 
two RCTs document benefits for calcium stone-formers with hypocitraturia, among whom 
ICSFs would statistically have predominated (20). Citrate is an excellent inhibitor of apatite 
nucleation and growth (28,29); however, citrate can raise urine pH and CaP SS, so we 
believe it is prudent to dose enough to reduce urine ammonia by one half to two thirds; more 
will almost certainly raise pH. For example, the initial dose in millimoles per day could be 
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one half to two thirds of the urine ammonia, in millimoles per day, as derived from standard 
commercially available 24-hour urine kidney stone risk panels.
Urine oxalate is far from trivial in any ICSF, so even in this CaP-oriented discussion we note 
that even with fixed and identical diets oxalate excretion is higher than normal in ICSFs, and 
CaOx SS is also higher, especially overnight (30). Moreover, ICSFs not infrequently exhibit 
renal oxalate secretion compared with normal control subjects eating the same diet (31), 
suggesting new mechanisms by which CaOx crystallization might be promoted. Lowering 
CaOx SS should reduce bulk nucleation and growth of CaOx on the new CaP stone nidus 
and is therefore very important. Urine oxalate excretion rates >45 mg/d often arise from low-
calcium or high-oxalate diets that can be corrected. Values >65 to 70 mg/d may reflect 
primary hyperoxaluria or enteric hyperoxaluria (20). No RCTs support reduction of urine 
oxalate as a treatment for ICSFs.
Finally, hyperuricosuria may reduce CaP and CaOx solubility via salting out and therefore 
raise the propensity for both nucleations (32–34). This is perhaps why a single RCT with 
allopurinol was so positive (35). Reduced diet purine should do as well, but no trial has been 
done.
RCTs Accord with the Model of Plaque Formation and Overgrowth
In an RCT of male ICSFs, a low sodium and protein diet was more effective in stone 
reduction than a low-calcium diet, which would not increase proximal tubule reabsorption 
(18). All three fully powered, 3-year thiazide trials (36–38) have been highly positive, as 
have the two RCTs with potassium citrate in hypocitraturic calcium stone-formers (39,40) 
and the one RCT with allopurinol in hyperuricosuric calcium stone-formers. The thiazide, 
citrate, and allopurinol RCTs concerned idiopathic calcium stone-formers, wherein ICSFs 
must have predominated, but some CaP stone-formers were surely also present.
The ICSFs Have a Specific Disease
Because IH can be linked to plaque via the known anatomy and physiology of the kidney, 
because their stones grow on plaque through a well defined series of nucleations, and 
because mechanisms and origins of IH itself also are becoming well known, the stone 
disease of IH can be understood from its etiology, through its pathogenesis to its eventual 
tissue expression. Given that the final disease, stones, can be so well explained in 
mechanistic terms, ICSFs appear to satisfy reasonable criteria of a cohesive disease of 
mineral metabolism. We note in leaving this subject that a generation of researches has 
established the remarkable abilities of urine to inhibit nucleation and growth of calcium 
crystals (41); abnormalities of inhibition may well be part of the ICSF phenotype, but 
evidence for this is scanty at best, and much more must be done before the matter has 
clinical relevance.
Idiopathic CaP Stone-Formers
Idiopathic CaP stone-formers (IPSFs) whose stones contain >50% CaP differ so radically 
from ICSFs that their stones might well come from an entirely different etiology and 
pathogenesis. However much they may resemble ICSFs on superficial analysis, they do not 
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have that disease. Instead, their kidneys are involved in a far more destructive local process. 
IPSFs could form stones of apatite or brushite (calcium monohydrogen phosphate); to date, 
we have data only on the latter group, brushite IPSFs, and what follows applies only to them.
IPSFs Plug BDs and IMCDs with Apatite Crystals
During PERC or URS, white plaque is present (Figure 7A, arrow); papillae show areas of 
scarring (arrowheads) and scattered hugely dilated BDs plugged with apatite crystals that 
often protrude out of the duct opening (42) and project into the urinary space (asterisk). On 
biopsy (Figure 7, B through F) affected BDs can be 20-fold dilated; epithelial cells are 
absent (arrow). Interstitial fibrosis surrounds affected BDs (legend details changes in each 
panel). Crystal-mediated injury essentially creates a focal papillary tubulointerstitial 
nephropathy.
The mechanism for plugging and high stone CaP abundance seems simply to be a high urine 
CaP SS (43). Mean urine CaP SS (Figure 8, left panel) of calcium stone-formers increases 
smoothly as the fraction of phosphate in stones analyzed increases (Figure 8, x-axes of both 
panels). This occurs because of rising urine pH (Figure 8, right panel). The reason for the 
increasing pH is not known. All groups of patients on these plots have equivalent IH. 
Because IMCD and BD tubule fluid approximates the final urine, CaP SS must be higher at 
both sites, leading to sporadic and damaging crystallizations.
The Less Abundant Plaque in IPSFs Raises Important Research Questions
Urine calcium excretion is slightly higher in IPSFs versus ICSFs, and urine volume is 
approximately the same, but the higher pH is predictive of less plaque. Vas washdown 
should operate the same way for both groups. However, at least two alternative mechanisms 
can reduce plaque. Reduced net proton secretion in IMCDs would be expected in IPSFs 
compared with ICSFs, and this would reduce bicarbonate entry into the papillary interstitium 
and therefore reduce interstitial fluid pH. Higher pH would foster CaP nucleation in 
basement membranes of thin loops.
Alternatively, medullary thick ascending limb may have reduced absolute calcium 
reabsorption in IPSFs compared with ICSFs. Although both exhibit the same urine calcium 
losses and even reduced overall tubule reabsorptive changes, IPSFs would not load 
descending vasa recta with calcium to the extent found in ICSFs. Because thick ascending 
limbs reabsorb approximately 15% of filtered bicarbonate (44), reduced reabsorption would 
increase distal bicarbonate delivery to IMCDs and BDs, raise the pH there, and foster CaP 
crystallization. In other words, IH may have several tubule expressions, one centered mainly 
in proximal tubules and one in thick ascending limbs with perhaps a spectrum in between 
these extremes. In inbred hypercalciuric rats, proximal tubule and thick ascending limb 
calcium reabsorptions are abnormally low (17). Comparison of nephron physiology in IPSFs 
versus ICSFs therefore offers remarkable opportunity for new human discoveries.
Management of IPSFs
The value of reduced diet sodium and protein, and of high fluid intake and thiazide, is the 
same as in ICSFs— what differs is the role of potassium citrate. Citrate is an inhibitor of 
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CaP nucleation and growth, as mentioned already, but if urine pH and therefore CaP SS 
rises, stones and plugging can increase. An RCT is badly needed for this exact kind of 
patient. Given that IPSFs are hardly rare, this trial is long overdue.
One does not have to wait for stone analysis. Any URS or PERC is an opportunity for 
surgeons to observe plugging, which is not present in ICSFs. The urologists who serve our 
patients should always be asked if plugging is seen and if even a crude estimate can be given 
of amounts of plugging and papillary retraction and scarring.
Summary
Information drawn from operative biopsies of the renal papillae in stone-formers is altering 
our understanding of the ways in which calcium stones form. The importance of plaque in 
formation of CaOx stones means that methods to reduce plaque formation should become a 
goal of stone prevention. The role that CaP SS plays in the formation of CaOx and CaP 
stones means that lowering CaP SS should be a goal for ICSFs and IPSFs. The marked 
histopathologic differences between ICSFs and IPSFs highlight the need for a trial to 
evaluate treatments for stone prevention in each group. As our understanding of the 
pathophysiology of stone formation improves, it will inform our ability to choose 
appropriate treatments for our patients.
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Figure 1. Endoscopic and histologic characteristics of interstitial plaque in idiopathic calcium 
oxalate stone-formers (ICSFs)
(A) Example of a papilla from an ICSF that was video recorded at the time of the mapping 
protocol. The papillary tip is covered by multiple sites of an irregular white material 
(arrows) termed “interstitial” or “Randall’s plaque” that is seen through the urothelial 
covering. These regions of plaque are sites for stone attachment. (B) Two small stones 
(asterisks) of approximately 0.5 mm are seen associated with a region of interstitial plaque 
(arrows). Histologic examination of papillary biopsies taken adjacent to sites of interstitial 
plaque shows that crystalline material (arrow in C) initially accumulates in the basement 
membranes of the thin loops of Henle. With time, these small sites of deposits appear to 
accumulate in the interstitial space as dense islands of mineral proceeding to the basal 
surface of the urothelial covering of a renal papilla (arrowhead in D). Adapted from 
references 2,8.
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Figure 2. Relationships between plaque abundance and urine findings
Fraction of papillary surface covered by plaque, as determined from intraoperative digital 
imaging (y-axis of all four panels), varies with urine calcium (upper right panel), and 
inversely with urine pH and volume (lower panels). A multivariable score using all three 
variables accounted for much of the variation in plaque coverage (upper left panel). ○, 
ICSFs; ● controls; △‚ patients with obesity bypass procedures. Score1, volume calcium pH 
score; Ca24, urine calcium (mg/day); UPH, urine pH; VOL24, Urine volume (liters/day). 
Adapted from reference 8.
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Figure 3. Schematic drawing of outer medulla and papillary tip
Vasa recta descend in bundles through the inner stripe of the outer medulla (upper panels) 
surrounded by rings of thick ascending limbs. In the papillary tips, where plaque forms in 
basement membranes of thin limbs (lower panels), thin limbs are each surrounded by three 
to four capillaries that derive from the descending vasa recta.
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Figure 4. Relationship between urine calcium excretion (y-axis) and delivery of calcium from 
proximal tubules (x-axis)
Urine calcium excretion increases with distal delivery from proximal tubules in ICSFs (black 
circles), whereas values for matched control subjects are clustered in the lower left quadrant 
(gray circles). Each point is the mean of 15 clearance periods during a three-meal day in the 
general clinical research center; subjects all ate the same diet. Proximal reabsorption was 
measured using endogenous lithium clearance. Adapted from reference 45.
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Figure 5. Transmission electron microscopic image of an attachment site of small calcium oxalate 
(CaOx) stone
This high-magnification micrograph shows the ultrastructural features of the plaque-stone 
interface. The upper left hand corner of the micrograph shows the stone material in the 
urinary space, whereas the lower right corner shows a region of interstitial plaque in the 
renal papilla. The plaque boundary denoted by a row of four arrowheads has the appearance 
of a multilayered ribbon. When the portion of this ribbon marked by a square is magnified 
(see inset at upper right), this ribbon-like structure is seen to have nine separate layers in 
which five thin black organic lamina alternate with four white lamina. In the thickest of the 
white lamina, one can see tiny spicules that run perpendicular to the surface and have the 
appearance of multiple voids that contain tightly packed crystals (small arrows in inset). The 
two white arrowheads seen in the insert mark the closest black lamina to the renal tissue. An 
asterisk marks a series of small crystals, whereas two large arrows mark a set of larger 
crystals that appear to be inserted in the outermost layer (urinary side) of the ribbon. All 
crystalline material appears to be covered by black matrix material. Adapted from reference 
25.
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Figure 6. Urine calcium phosphate (CaP) and CaOx supersaturation (SS) throughout a three-
meal day in ICSFs (gray bars) and normal controls (black bars)
Subjects all ate identical diets and were studied using 15 urine collections during fasting 
(Fast), from breakfast to lunch (B to L), lunch to supper (L to S), supper to home (S to H), 
and overnight (ON). CaP SS (lower right panel) of ICSFs exceeded normal controls in the 
last three periods of the day, and normal controls never achieved an average SS >1 
(horizontal dashed line). The main cause of the high CaP SS was urine calcium molarity 
(upper left panel), which itself arose from hypercalciuria without an accompanying increase 
of urine volume (lower middle panel). Urine pH values did not differ significantly (lower left 
panel). Urine CaOx SS of ICSFs exceeded that of normal controls (upper right panel), 
mainly because of higher calcium molarity; urine oxalate molarity did not differ (upper 
middle panel). Adapted from reference 46.
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Figure 7. Endoscopic and histologic images of crystalline deposition in brushite stone patients
Endoscopic examination of papilla from brushite stone-formers reveals a wide range of 
pathologies from normal to severe deformities. (A) A papilla with extensive pitting marked 
by a series of arrowheads and extensive dilation of the distal end of ducts of Bellini (BDs) 
usually filled with a protruding crystalline plug (asterisk). Small regions of Randall’s plaque 
(single arrow in A) termed “type 1 crystal pattern” were commonly seen. Histologic 
examination of papillary biopsies reveals enormously dilated inner medullary collecting 
ducts (IMCDs) and BDs (arrow in B) with mineral occasionally protruding (asterisk in B) in 
the urinary space. Sites of interstitial plaque are seen (double arrow in B). Other papilla 
possessed sites of Randall’s plaque (double arrows in C) and regions of yellow plaque 
(single arrows in C) termed “type 2 crystal pattern.” Each site of yellow plaque was linear in 
orientation, and when multiple such areas were near each other they formed a spoke- and 
wheel-like pattern (C). Histologic examination of a single site of yellow plaque revealed 
these areas represented IMCDs filled with mineral (asterisk in D) that was positioned just 
beneath the urothelial covering (single arrow in D). Double arrow in panel D marks a site of 
Randall’s plaque. Light microscopic examination of Yasue-stained sections revealed that the 
plugged IMCDs contained large amounts of mineral (arrow in E) that filled the lumens of 
severely damaged tubules whereas nearby tubules appeared normal. Mineral deposits were 
also seen in thin loops of Henle (asterisk in E). Tissue sections stained with hemotoxylin and 
eosin revealed crystalline-filled IMCDs (arrows in F) embedded in a region of interstitial 
fibrosis. Adapted from reference 42.
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Figure 8. Urine CaP SS and pH in stone-formers with increasing stone CaP abundance
Calcium stone-formers were grouped by percent CaP in all analyzed stones (x-axis). CaP SS 
(left panel, y-axis) rose progressively with percent CaP in stones; the main reason was a 
progressive increase in urine pH (right panel, y-axis). Urine calcium and phosphate 
excretions (not shown) did not vary across stone percentage categories. Women (gray 
circles) and men (black circles) showed essentially identical behavior. Adapted from 
reference 43.
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